1. Thyroglobulin cutoffs after total thyroidectomy without radioiodine in low-to intermediate-risk thyroid cancer: a multicenter cohort sutdy. Thyroid.2026; 36 (1): 45-56
2. Effect of thyroid-stimulating hormone suppression on bone mineral density in patients with differentiated thyroid carcinoma: a single center retrospective study. J Bone Metab. 2025; 32(3):221-231
3. Preoperative controlling nutritional status score for pateints with medullary thyroid cancer. Endocrine. 2025; 89:476-483
4. The impact of chronic diseases on non-invasive blood glucose measurement using near-infrared spectroscopy in republic of Korea: retrospective clinical study. Med Lsers. 2025;14(4):244-252
5. Dynamic risk model for the medical treatment of Graves’ hyperthyroidism according to treatment duration. Endocrinol Metab (Seoul). 2024; 39 (4): 579-589
6. Prognostic roles of inflammatory biomarkers in radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrinol Metab (Seoul). 2024; 39 (2): 334-343
7. Acute thyrotoxicosis following a horse-induced neck trauma. International Journal of Thyroidology. 2024;17 (1): 245-249
8. Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib. Sci Rep.2023;12 (1):12765
9. Long-term follow-up result of antithyroid drug treatment of Graves hyperthyroidism in a large cohort. Eur Thyroid J.2023;12(2)
10. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib. Endocrine. 2023;81(2):298-305
11. Serum thyroglobulin testing after thyroid lobectomy in patients with 1-4cm papillary thyroid carcinoma. Endocrine. 2023;81(2):290-7.
12. Prognosis of Patients with 1-4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles. 2022, Ann Surg Oncol. doi: 10.1245/s10434-022-12155-2.
13. Limitations of fine-needle aspiration and core needle biopsies in the diagnosis of tall cell variant of papillary thyroid carcinoma. 2022, Clin Endocrinol (Oxf). doi: 10.1111/cen.14735.
14. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study. 2022, Thyroid. doi: 10.1089/thy.2022.0054.
15. Immunoglobulin G4-Related Thyroid Disease: A Single-Center Experience and Literature Review. Endocrinol Metab (Seoul). 2022; 37:312-322.
16. Effect of TSH levels during active surveillance of PTMC according to age. 2022, Endocr Relat Cancer. 2022; 29:191-200.
17. Graves disease diagnosed in remnant thyroid after lobectomy for thyroid cancer. 2022, PLoS One 17:e0265332.
18. Comparison of 99mTc Pertechnetate Thyroid Uptake Rates by Gamma Probe and Gamma Camera Methods for Differentiating Graves’ Disease and Thyroiditis. Nuclear Medicine and Molecular Imaging 2022; 56:42-51.
19. Clinical Characteristics and Prognosis of Coexisting Thyroid Cancer in Patients with Graves Disease: A Retrospective Multicenter Study. Endocrinol Metab (Seoul). 2021;36:1268-1276.
20. Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF(V600E)-Mutant Advanced Papillary Thyroid Carcinoma. 2021, Cancers (Basel) 13.
21. Death-Associated Protein Kinase 1 Inhibits Progression of Thyroid Cancer by Regulating Stem Cell Markers. 2021, Cells 10.
22. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry. 2021, Thyroid 31:61-67.
23. Clinicopathological Characteristics and Disease-Free Survival in Patients with Hurthle Cell Carcinoma: A Multicenter Cohort Study in South Korea. 2021, Endocrinol Metab (Seoul) 36:1078-1085.
24. Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Microcarcinoma: A Multicenter Cohort Study in Korea. 2021, Thyroid 31:1494-1501.
25. Clinical implications of age and excellent response to therapy in patients with high-risk differentiated thyroid carcinoma. 2021, Clin Endocrinol (Oxf) 95:882-890.
26. SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer. 2021, Endocr Connect 10:630-636.
27. Anaplastic Thyroid Carcinoma with Initial Ultrasonography Features Mimicking Subacute Thyroiditis. 2021, Endocrinol Metab (Seoul) 36:201-202.
28. Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas. 2021, Cancers (Basel) 13.
29. Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis. 2020, Endocrinol Metab (Seoul) 35:830-837.
30. Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study. 2020, Endocrinol Metab (Seoul) 35:618-627.
31. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy. 2020, Endocrinol Metab (Seoul) 35:602-609.
32. A Case of Severe Pneumocystitis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib. 2019, International Journal of Thyroidology 12:127-131.
